Arrow Capital’s AstraZeneca AZN Stock Holding History

Arrow Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$5.82M	–	28
2026 Q1	$5.82M	Buy	+30,000	New	+$5.78M	5.82%	7

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Arrow Capital's AZN Position: Q2 2026 in Review

Arrow Capital sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 30,000 shares — an estimated $5.82M sold.

Arrow Capital first reported a position in AZN in Q1 2026 and held it in 1 quarter. The position peaked at $5.82M in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Arrow Capital reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Arrow Capital sold 30,000 AstraZeneca shares in Q2 2026, an estimated $5.82M.
Arrow Capital first reported a position in AstraZeneca in Q1 2026 and held it in 1 quarter.
Arrow Capital's AstraZeneca position peaked at $5.82M in Q1 2026.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Arrow Capital's 13F filing for Q2 2026, filed 5 Aug 2026.